Impact of mirikizumab maintenance dosing on patients who had < PASI 90 response at week 16: A phase 2 study analysis using the DLQI

The objective of this study is to determine whether mirikizumab maintenance dosing improves health-related quality of life (HRQoL) as measured by the Dermatology Life Quality Index (DLQI) in patients who had
Source: Journal of the American Academy of Dermatology - Category: Dermatology Source Type: research